Thomas Cannell, Sesen Bio CEO

Sesen Bio paus­es blad­der can­cer drug work, of­floads eye dis­ease an­ti­bod­ies to Roche

Fol­low­ing an FDA re­jec­tion last year, Sesen Bio an­nounced this morn­ing that it will be paus­ing de­vel­op­ment on its lead blad­der can­cer drug.

With the pause, Sesen can save mon­ey while it looks for al­ter­na­tives, the Cam­bridge, MA-based biotech said in a press re­lease. It not­ed that it would be look­ing for a part­ner for its blad­der can­cer drug Vicineum.

In Au­gust, the FDA re­ject­ed Vicineum — which the biotech as­cribed to man­u­fac­tur­ing is­sues and the FDA ask­ing for more da­ta. The biotech said its de­ci­sion for paus­ing de­vel­op­ment came af­ter as­sess­ing costs for an ad­di­tion­al Phase III tri­al for the drug in blad­der can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA